Pfi$er.
Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance
Link (subscriber-only) : Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance - Metsera (NASDAQ:MTSR), Eli Lilly (NYSE:LLY) - Benzinga
See how fast things are moving!
I noticed that this drug has been getting a lot of promotion in UK news, mostly from the viewpoint of can patients get it, when and how etc:
Fears over āpostcode lotteryā for NHS weight-loss drug access in Scotland
Have we been here before? (Strokes beard). The fear is of āmissing outā!
Obesity experts point to flaw in Trumpās weight loss drug deal despite price cuts and expanded eligibility
Studies have shown that many patients regain weight after stopping the medication
Thatās not the only flaw, nor the most serious. Obviously the drug, which although it can treat the symptoms, it is not a cure for what led to the weight gain in the first place. We donāt need scentists to tell us that. But what about safety?
Itās a relatively new drug which has only been tested for diabetes; but there are plenty of wellā¦flags. Not what you want to see when the hype precedes the safety evaluation and suddenly there is a huge market for it stoked by the media.
CHD points up some of the flags.
Can Weight-Loss Drugs Cause Cancer? The Data Are Mixed
The surge in use of the growing class of GLP-1 receptor agonists ā which include blockbuster drugs like Ozempic, Wegovy and Mounjaro ā to treat obesity and Type 2 diabetes is prompting scrutiny over the drugsā possible links to cancer. A review by TrialSite News of the latest science found mixed results.
ā¦ ā¦
ā¦ ā¦
Cancer is just the latest concern over weight loss drugs. CHD notes that:
āBlockbuster drugs like Ozempic, Wegovy and Mounjaro, used to treat obesity and Type 2 diabetes, have been associated with serious side effects, including dental decay, loss of muscle and bone mass, blindness, suicidal ideation and death.ā
It seems there is a lot of study - and waiting - to be done before NORMAL drug safety protocols can be said to be met.
āConflicting evidenceā does mean a possible risk. This is because conclusions of harm have to (by convention) meet a threshold of 95% significance.
If even (eg) only half of studies say record association with a given harm, then though the level of significance would be reduced, there is some risk to be addressed - making the drug unsuitable for blind rollouts, state-marketing (note the presence of the Orange Man in the Indy story) and hype-fuelled demand making due safety based control impossible.
ED